Nimitt is a specialized consulting firm that provides strategic consulting, analysis, and education on health care reimbursement and the factors that drive it. We have expertise in reimbursement for innovative new treatments in the realm of cell and gene therapies.
Clients come to Nimitt for our in-depth experience with payment systems, including rate-setting, coding, compliance, and provider operations. Our clients know that Nimitt’s team will listen intensely, fully explore operational challenges, engage stakeholders in dynamic ways, and help identify—and implement—solutions that work.
Nimitt is a leader in this space due to our long-standing collaboration and deep familiarity with both provider operations and issues that create barriers to patient access. We bring this expertise to advocate for coverage, coding, billing, and reimbursement changes to ensure that therapies—both existing and new—can be successfully brought to patients.
Our long-standing data-driven advocacy efforts have resulted in significant payment policy changes in the cell therapy space, specifically for stem cell transplant and Chimeric Antigen Receptor T cell (CAR-T) therapy. We have also had notable successes updating Medicare’s payment methodologies for surgical and medical procedures (including injections, infusions, and device-intensive procedures) and Part B drugs. Nimitt led the efforts that resulted in new ICD-10 procedure and diagnosis codes and numerous policy changes to CMS’ inpatient, outpatient, and physician fee schedule payment policies to better reflect providers’ real-world experience in delivering care. We are proud to have helped improve coverage and gain new codes that accurately reflect, and appropriately value, innovative medical advancements.
We are focused and committed to understanding our clients’ needs in order to improve patient access and reimbursement, by working to reduce the day-to-day operational burden of our provider clients, while also supporting industry client, professional associations, and payers as they bring new therapies to market.